Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Inoue, A.
Right arrow Articles by Nukiwa, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Inoue, A.
Right arrow Articles by Nukiwa, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:51-54, 2004
© 2004 European Society for Medical Oncology

Original Paper

Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis

Received 25 April 2003; revised 6 August 2003; accepted 13 August 2003

Background:

The aim of this study was to use pharmacokinetic analysis to investigate the efficacy and toxicity of combined chemotherapy with carboplatin (CBDCA) and etoposide (ETP) in small-cell lung cancer (SCLC) patients with chronic renal failure undergoing hemodialysis (HD).

Patients and methods:

Three SCLC patients with chronic renal failure undergoing HD were treated with CBDCA (300 mg/m2) on day 1 and ETP (50 mg/m2) on days 1 and 3, followed by HD 1 h after completing the administration of anticancer agents on each day. The pharmacokinetic analysis of CBDCA and ETP was planned for at least the first two courses of the chemotherapy in each patient.

Results:

Two complete responses and one partial response were achieved in the three patients. Two patients experienced grade 3/4 neutropenia and required blood transfusion due to thrombocytopenia and anemia. Non-hematological toxicities were moderate. The pharmacokinetic analysis revealed that the platinum and the ETP concentrations in the plasma were similar to those in patients with normal renal function during the first 24 h, while the platinum still remained in the plasma for over 90 h.

Conclusions:

Chemotherapy with CBDCA (300 mg/m2 on day 1) and ETP (50 mg/m2 on day 1, 3) as used in the present study may be a suitable regimen for SCLC patients undergoing HD, although careful attention should be given to hematological toxicities.

A. Inoue1,*, Y. Saijo1,2, T. Kikuchi1, K. Gomi1, T. Suzuki1, M. Maemondo1, M. Miki3, T. Sato4 and T. Nukiwa1

1 Department of Respiratory Oncology and Molecular Medicine, Institute of Development, Aging and Cancer, Tohoku University, Sendai; 2 Department of Molecular Medicine and Gene Transfer Research; 3 Department of Respiratory Medicine, Japanese Red Cross Sendai Hospital, Sendai; 4 Department of Blood Purification, Tohoku University Graduate School of Medicine, Sendai, Japan

Key words: carboplatin, chemotherapy, hemodialysis, pharmacokinetics, small-cell lung cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
H. M. Pettersson, A. Pietras, M. Munksgaard Persson, J. Karlsson, L. Johansson, M. C. Shoshan, and S. Pahlman
Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells
Mol. Cancer Ther., January 1, 2009; 8(1): 160 - 170.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
K. Hochegger, K. Lhotta, G. Mayer, M. Czejka, and W. Hilbe
Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer
Nephrol. Dial. Transplant., January 1, 2007; 22(1): 289 - 290.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
B. Boesler, D. Czock, F. Keller, M. Griesshammer, T. Seufferlein, W. Karges, and F. M. Rasche
Clinical course of haemodialysis patients with malignancies and dose-adjusted chemotherapy
Nephrol. Dial. Transplant., June 1, 2005; 20(6): 1187 - 1191.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.